Citius Pharmaceuticals, Inc. · NASDAQ:CTXR
Citius Pharmaceuticals — Investor Presentation (October 2025)
26 slides from Citius Pharmaceuticals's investor presentation, Oct 23, 2025
Slide 1: Citius Pharmaceuticals Corporate Overview October 2025
NASDAQ: CTXR Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) Corporate Overview OCTOBER 2025 Exhibit 99.1
Slide 2: Forward-Looking Statements
This presentation has been prepared by Citius Pharmaceuticals, Inc . (the “Company”) for informational purposes only and not for any other purpose . Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the Company or any director, emplo
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS Biopharmaceutical company with multiple advanced development programs • LYMPHIR (denileukin diftitox - cxdl) • APPROVED for the treatment of cutaneous T - cell lymphoma (CTCL) • Commercialization planned in Q4 2025 • Spun - off into Citius Oncology, Inc. (NASDAQ: CTOR) in Augus
Slide 4: About Citius Oncology, Inc.
NASDAQ: CTXR ABOUT CITIUS ONCOLOGY, INC. (NASDAQ: CTOR) 4 1. Internal estimates based on IQVIA market research. 2. Intended distribution timing subject to performance, market conditions, and other factors including applicable restrictions on transfer. Biopharmaceutical company focused on developing
Slide 5: Citius Is Preparing to Launch LYMPHIR in Q4 2025
NASDAQ: CTXR CITIUS IS PREPARING TO LAUNCH LYMPHIR IN Q4 2025 Citius has invested >$90 million in LYMPHIR to date $40M Upfront purchase $43M Development and precommercial efforts $5M Spinout to form Citius Oncology Significant pre - commercial activities have been completed Manufactured inventory fo
Slide 6: What Is Cutaneous T-Cell Lymphoma (CTCL)?
NASDAQ: CTXR 6 WHAT IS CUTANEOUS T - CELL LYMPHOMA (CTCL)? Considered to be incurable, CTCL is a Subgroup of Non - Hodgkin Lymphomas (NHL) that can be Indolent or Aggressive and is Driven by Malignant T Cells CTCL is a general term for T - cell lymphoma that involves the skin, but may also involve t
Slide 7: CTCL Patients Have a High Disease Burden
CTCL PATIENTS HAVE A HIGH DISEASE BURDEN T1 T4 Sézary cell T2 T3 Zackheim. J Am Acad Dermatol. 1999;40:418. Slide credit: clinicaloptions.com NASDAQ: CTXR 7
Slide 8: Differentiated Mechanism of Action (MOA)
DIFFERENTIATED MECHANISM OF ACTION (MOA) LYMPHIR targets the IL - 2 receptor, working both as a targeted therapy against malignant T - cells AND as an immunotherapy against Tregs IL - 2 receptor offers a unique treatment opportunity in CTCL Malignant T - cells and Tregs share a common marker: the IL
Slide 9: Competitive Landscape
COMPETITIVE LANDSCAPE Today’s CTCL treatments are non - curative LYMPHIR excels where current therapies are limited • Requires CD30+ biomarker • Peripheral neuropathy may limit use • Most effective in SS subsegment of CTCL (<5%) • Acts on blood disease rather than skin disease • ORR 21% in MF • Use
Slide 10: Very Concentrated Prescriber Base
VERY CONCENTRATED PRESCRIBER BASE 10% of Providers (Physicians) Treat ≥3 Patients 90 17 7 15 12 0 10 20 30 40 50 60 70 Number of Accounts 80 90 100 20 - 40 41 - 60 61 - 80 81 - 120 121 - 475 Number of Patients Accounts by Number of Diagnosed Patients 3928, 90% 427, 10% Providers treating at least 1
Slide 11: Patient and HCPs Clustered Near Major Cancer Centers
PATIENT AND HCPS CLUSTERED NEAR MAJOR CANCER CENTERS • Concentration of providers and accounts allows for a focused field force approach (~ 25 reps) • AI - driven trigger system will direct the field force to optimize opportunities with providers and patients Powered by Bing © GeoNames, Microsoft, T
Slide 12: Distribution Readiness and Channel Access
DISTRIBUTION READINESS AND CHANNEL ACCESS Patient - Centric Distribution Strategy aims to provide timely product availability for eligible CTCL patients across all care settings, reinforcing Citius’ commitment to access • Nationwide U.S. distribution network established • All major distribution agre
Slide 13: Opportunities for Growth Beyond CTCL
OPPORTUNITIES FOR GROWTH BEYOND CTCL • University of Pittsburgh: an investigator - initiated trial is underway to evaluate LYMPHIR for potential use as an immuno - oncology therapy in combination with KEYTRUDA® in patients with recurrent or metastatic solid tumors (NCT05200559) • Encouraging prelimi
Slide 14: LYMPHIR Is Competitively Positioned
LYMPHIR IS COMPETITIVELY POSITIONED • Differentiated MOA targeting the IL - 2 receptor reinforces rationale for inclusion among the current core therapeutic options in the U.S. market • CTCL treatments are non - curative , often have a limited duration of response and/or are discontinued early • Pat
Slide 15: Mino-Lok Phase 3 Trial Completed: Positive Topline Data
MINO - LOK NASDAQ: CTXR 15 Phase 3 Trial Completed: Positive Topline Data
Slide 16: Mino-Lok Overview
NASDAQ: CTXR MINO - LOK OVERVIEW Achieved primary and secondary endpoints of Phase 3 Trial x Time to catheter failure exceeded expectations x Majority of patients in the Mino - Lok group achieved overall treatment success x Well tolerated with no drug - related serious adverse events A novel antibio
Slide 17: Central Venous Catheters
CENTRAL VENOUS CATHETERS NASDAQ: CTXR 17 Central Venous Catheters (CVCs), Peripherally Inserted Central Catheter (PICCs), and Hemodialysis Central Venous Catheter PICC Hemodialysis
Slide 18: Biofilm Formation Protects Colonies
BIOFILM FORMATION PROTECTS COLONIES • Pathogens attach to the surface of the lumen in a central venous catheter and form colonies. • Colonies grow and exude a fibrous glycocalyx that protects the organisms from antibiotics, even when shown to be sensitive in vitro NASDAQ: CTXR 18
Slide 19: Market Potential: $1B+ in US and $2B+ Globally
MARKET POTENTIAL: $1B+ IN US AND $2B+ GLOBALLY High incidence of catheter - related infections support need for effective treatment options ~500,000 CRBSI/CLABSI infections annually in the U.S.** 12 - 25% CRBSI/CLABSI associated mortality & morbidity** * Shah H., Bosch W., Hellinger W. C., Thompson
Slide 20: Potential to Change Standard of Care
POTENTIAL TO CHANGE STANDARD OF CARE Mino - Lok addresses the complications, discomfort and cost of CVC removal and replacement salvage existing catheters Limited duration IV therapy designed to eradicate bacterial colonization with a short 2 - hour dwell time Limits disruption of infusion therapy a
Slide 21: Mino-Lok Phase 3 Trial Topline Results
MINO - LOK PHASE 3 TRIAL TOPLINE RESULTS NASDAQ: CTXR 21 Mino - Lok significantly outperforms hospital - specific anti - infective lock solutions • Kaplan Meier Analysis demonstrated clear separation between Mino - Lok and control arms, illustrating Mino - Lok’s superiority in extending time to cath
Slide 22: Halo-Lido Halobetasol/Lidocaine
HALO - LIDO NASDAQ: CTXR 22 Halobetasol/Lidocaine
Slide 23: Halo-Lido Overview
NASDAQ: CTXR • 10+ Million patients report symptoms of hemorrhoidal disease; 1/3 seek physician treatment 1 • A cream formulation containing halobetasol propionate (highly potent steroid) and Lidocaine HCl • Phase 2b enrollment completed • 5 cohorts of 60 subjects each • Primary endpoint: reduction
Slide 24: Summary
SUMMARY XCITIUS PHARMA moma m
Slide 25: Why Invest? Why Now?
WHY INVEST? WHY NOW? NASDAQ: CTXR 25 Diversified late - stage biopharmaceutical company with commercialization anticipated in 2025 • LYMPHIR poised to launch in Q4 2025 • $400+M est. addressable market with multiple opportunities for growth • First new systemic CTCL therapy since 2018 • 12 - year BL
Slide 26: Investor Inquiries
NASDAQ: CTXR Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) Investor Inquiries ir@citiuspharma.com
Citius Pharmaceuticals — Investor Presentation (October 2025) on 6ix